Amneal Pharmaceuticals, Inc. (AMRX)

From the record

Amneal Pharmaceuticals, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2023-12-15); an auditor change (8-K item 4.01, the latest 2018-05-07) (its current reports).

From the record

Amneal Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $1.0 billion in fiscal 2016 to $3.0 billion in fiscal 2025, up 12.8% a year; it rose in 8 of 9 years; the deepest fall was 2% from fiscal 2018 to fiscal 2019; net income was positive in 3 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Amneal Pharmaceuticals, Inc.'s diluted share count grew about 29.1% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 7 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Amneal Pharmaceuticals, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 30 cents per dollar of everything the company owns. Leverage: it owed about 102 cents per dollar of assets, and net share issuance: its share count grew 5.1% over the year (the filed statements).

From the record

Amneal Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $3.0 billion in fiscal 2025 ranks in the top 8% by size; a net margin of 2.4% ranks in the top 22%; revenue growth of 10.9% a year over the last 3 filed years ranks in the top 47% (its annual reports).

From the record

Amneal Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Patel, Chintu (Co-CEO, as filed), filing under that title since 2020-03-02, 6.7 years (top 30% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 7.9 years (top 21%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Amneal Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $282 million against debt of $2.6 billion leaves -62.3% of its assets as net cash, bottom 1% of its family; cash from operations less capital spending is 8.9% of revenue (top 22%); a gross margin of 36.9% (bottom 20%); research spending of 6.2% of revenue (bottom 7%) (its annual report).

From the record

Amneal Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 10.9% a year over the last three filed years against 12.8% over all 10, slowing (bottom 49% of its family); the newest year grew 8.1% (top 49%); research spending grew -1.6% a year (bottom 45%); capital spending grew 14.7% a year (top 27%) (its annual reports). Amneal Pharmaceuticals, Inc. reported 3 lines of business in fiscal 2025: Affordable Medicines at $1.7 billion, Av KARE at $745 million, Specialty at $529 million. 3 of 3 grew in the latest filed year, and the largest line is 58% of revenue (its annual report).

From the record

Amneal Pharmaceuticals, Inc.'s newest year against its own record: revenue of $3.0 billion in fiscal 2025 came in 3.8% below the $3.1 billion its prior three years' pace pointed to (bottom 46% of its family); net income of $72 million against a prior three-year average of $157 million (top 11%); a net margin of 2.4% against -6.6% before (bottom 48%) (its annual reports).